The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Metformin and Pathologic Complete Responses to Neoadjuvant Chemotherapy in Diabetic Patients With Breast Cancer
Open accessAbstract
Purpose: Population studies have suggested that metformin use in diabetic patients decreases cancer incidence and mortality. Metformin inhibits the growth of cancer cells in vitro and tumors in vivo. However, there is little clinical data to support this. Our purpose was to determine whether metformin use was associated with a change in pathologic complete response (pCR) rates in diabetic patients with breast cancer receiving neoadjuvant chemotherapy. Patients and Methods: We identified 2,529 patients who received neoadjuvant chemotherapy for early-stage breast cancer between 1990 and 2007. Patients were compared by groups: 68 diabetic patients taking metformin, 87 diabetic patients not taking metformin, and 2,374 nondiabetic patients. pCR rates were compared between the three groups using χ 2 tests of independence and compared pair- wise using a binomial test of proportions. Factors predictive of pCR were assessed using a multivariate logistic regression model. Results: The rate of pCR was 24% in the metformin group, 8.0% in the nonmetformin group, and 16% in the nondiabetic group (P = .02). Pairwise comparisons between the metformin and nonmetformin groups (P = .007) and the nonmetformin and nondiabetic groups (P = .04) were significant. Comparison of the pCR rates between the metformin and nondiabetic groups trended toward but did not meet significance (P = .10). Metformin use was independently predictive of pCR (odds ratio, 2.95; P = .04) after adjustment for diabetes, body mass index, age, stage, grade, receptor status, and neoadjuvant taxane use. Conclusion: Diabetic patients with breast cancer receiving metformin and neoadjuvant chemotherapy have a higher pCR rate than do diabetics not receiving metformin. Additional studies to evaluate the potential of metformin as an antitumor agent are warranted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Metformin has also been found to cooperate with neo-adjuvant chemotherapy to result in complete tumor regression in some breast cancer patients (Jiralerspong et al., 2009).”
From Targeting Metabolism for Cancer Therapy (2017) · cites this paper as Jiralerspong et al., 2009
In the citing paper
“Type 2 diabetic patients receiving neo-adjuvant chemotherapy for breast cancer as well as metformin were more likely to have pathologic complete response (pCR) than patients not receiving it.”
From Metformin: An Old But Still the Best Treatment for Type 2 Diabetes (2013) · cites this paper as [156]
In the citing paper
“However, despite the increase in pCR, metformin did not significantly improve the estimated 3-year relapse-free survival rate [156].”
From Metformin: An Old But Still the Best Treatment for Type 2 Diabetes (2013) · cites this paper as [156]
In the citing paper
“evidence that metformin may also have an adjunctive effect in patients receiving chemotherapy(270)”
From Metformin, the Aspirin of the 21st Century: Its Role in Gestational Diabetes Mellitus, Prevention of Preeclampsia and Cancer, and the Promotion of Longevity (2017) · cites this paper as [270]
In the citing paper
“There is further evidence that metformin may also have an adjunctive effect in patients receiving chemotherapy(270), and there are now more than 100 ongoing trials”
From Metformin, the Aspirin of the 21st Century: Its Role in Gestational Diabetes Mellitus, Prevention of Preeclampsia and Cancer, and the Promotion of Longevity (2017) · cites this paper as [270]
In the citing paper
“Metformin treatment was associated with higher pathologic complete response among early-stage breast cancer patients receiving neoadjuvant therapy (95).”
From Diabetes and Cancer (2010) · cites this paper as [95]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. Adults
Calle, E. E., Rodriguez, C., Walker-Thurmond, K., & Thun, M. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021423 · Cited by 7,696
Renehan, A. G., Tyson, M., Egger, M., Heller, R. F., & Zwahlen, M. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60269-x · Cited by 5,219
TSC2 Mediates Cellular Energy Response to Control Cell Growth and Survival
Inoki, K., Zhu, T., & Guan, K.-L. (2003) · Cell · doi:10.1016/s0092-8674(03)00929-2 · Cited by 3,914
Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms
Calle, E. E., & Kaaks, R. (2004) · Nature reviews. Cancer · doi:10.1038/nrc1408 · Cited by 3,613
Metformin and reduced risk of cancer in diabetic patients
Evans, J. M. M., Donnelly, L. A., Emslie-Smith, A. M., Alessi, D. R., & Morris, A. D. (2005) · BMJ · doi:10.1136/bmj.38415.708634.f7 · Cited by 2,388
The Kinase LKB1 Mediates Glucose Homeostasis in Liver and Therapeutic Effects of Metformin
Shaw, R. J., Lamia, K. A., Vasquez, D., Koo, S.-H., Bardeesy, N., DePinho, R. A., Montminy, M., & Cantley, L. C. (2005) · Science · doi:10.1126/science.1120781 · Cited by 1,950
Rastogi, P., Anderson, S. J., Bear, H. D., Geyer, C. E., Kahlenberg, M. S., Robidoux, A., Margolese, R. G., Hoehn, J. L., Vogel, V. G., Dakhil, S. R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.0235 · Cited by 1,789
Insulin-like growth factors and neoplasia
Pollak, M., Schernhammer, E. S., & Hankinson, S. E. (2004) · Nature reviews. Cancer · doi:10.1038/nrc1387 · Cited by 1,477
Molecular and metabolic mechanisms of insulin resistance and β-cell failure in type 2 diabetes
Muoio, D. M., & Newgard, C. B. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2327 · Cited by 1,177
The LKB1 tumor suppressor negatively regulates mTOR signaling
Shaw, R. J., Bardeesy, N. M., Manning, B. D., Lopez, L. V., Kosmatka, M., DePinho, R. A., & Cantley, L. C. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.06.007 · Cited by 1,107
Flagged first, then by citations
Research works printed but not linked: 3
- Mieog JS, 2007, Cochrane Database Syst Rev, 2, CD005002
- 10.1200/JCO.2002.20.1.42 · DOI
- Fairey AS, 2003, Cancer Epidemiol Biomarkers Prev, 12, 721
Cited by
Sorted by citations
Items 301–400 of 879
Khan, A. Q., Hasan, A., Mir, S. S., Rashid, K., Shahab Uddin, M. S., & Steinhoff, M. S. (2024) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2024.03.002 · Cited by 60
Gong, J., Kelekar, G., Shen, J., Shen, J., Kaur, S., & Mita, M. M. (2016) · Targeted Oncology · doi:10.1007/s11523-016-0423-z · Cited by 56
Yu, Z., Zhao, G., LI, P., Li, Y., Zhou, G., Chen, Y., & Xie, G. (2016) · Oncology Letters · doi:10.3892/ol.2016.4315 · Cited by 54
A phase I study of temsirolimus and metformin in advanced solid tumours
MacKenzie, M. J., Ernst, S., Johnson, C., & Winquist, E. (2010) · Investigational New Drugs · doi:10.1007/s10637-010-9570-8 · Cited by 53
“Further, a large retrospective review has shown that rates of complete pathologic response were higher in patients taking metformin during neoadjuvant chemotherapy for breast cancer [15].”
BackgroundTseng, S.-C., Huang, Y., Chen, H.-J., Chiu, H., Huang, Y., Wo, T., Weng, S., & Lin, Y. (2012) · Biochemical Pharmacology · doi:10.1016/j.bcp.2012.12.001 · Cited by 55
Berstein, L. M., Yue, W., Wang, J., & Santen, R. J. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-1072-z · Cited by 55
“Women with diabetes receiving MF and neoadjuvant chemotherapy experienced a higher pathologic complete response rate than did diabetic patients not receiving this drug [23].”
BackgroundMetformin enhances the response to radiotherapy in diabetic patients with rectal cancer
Oh, B. Y., Park, Y. A., Huh, J. W., Cho, Y. B., Yun, S. H., Lee, W. Y., Park, H. C., Choi, D. H., Park, Y. S., & Kim, H. C. (2016) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-016-2148-x · Cited by 52
Zou, J., Hong, L., Luo, C., Li, Z., Zhu, Y., Huang, T., Zhang, Y., Yuan, H., Hu, Y., Wen, T., et al. (2016) · Cancer Science · doi:10.1111/cas.13083 · Cited by 53
Richards, K. A., Liou, J., Cryns, V. L., Downs, T. M., Abel, E. J., & Jarrard, D. F. (2018) · The Journal of Urology · doi:10.1016/j.juro.2018.06.031 · Cited by 52
Ariaans, G., Jalving, M., Vries, E. G. E. D., & Jong, S. D. (2017) · BMC Cancer · doi:10.1186/s12885-017-3230-8 · Cited by 51
“Moreover, epidemiological evidence and retrospective clinical data indicate, that metformin has intrinsic anti-cancer properties [10, 11].”
BackgroundZamanian, M. Y., Golmohammadi, M., Yumashev, A., Hjazi, A. M., Toama, M. A., AbdRabou, M. A., Gehlot, A., Alwaily, E. R., Shirsalimi, N., Yadav, P. K., et al. (2024) · Cell Biochemistry and Function · doi:10.1002/cbf.4071 · Cited by 53
Molecular Pathways: Preclinical Models and Clinical Trials with Metformin in Breast Cancer
Thompson, A. M. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0354 · Cited by 50
Targeting Cell Metabolism as Cancer Therapy
Ngoi, N. Y. L., Eu, J. Q., Hirpara, J. L., Wang, L., Lim, J. S. J., Lee, S. C., Lim, Y., Pervaiz, S., Goh, B. C., & Wong, A. L. A. (2019) · Antioxidants and Redox Signaling · doi:10.1089/ars.2019.7947 · Cited by 52
The BATTLE to Personalize Lung Cancer Prevention through Reverse Migration
Gold, K. A., Kim, E. S., Lee, J. J., Wistuba, I. I., Farhangfar, C. J., & Hong, W. K. (2011) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-11-0232 · Cited by 51
The Effect of Metformin on Mortality Following Cancer among Patients with Diabetes
Lega, I. C., Shah, P. S., Margel, D., Beyene, J., Rochon, P. A., & Lipscombe, L. L. (2014) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-14-0327 · Cited by 53
“Metformin exposure has been associated with improved surrogate prognostic markers in patients with breast cancer, such as pathologic complete response following chemotherapy (14) and decreased cellular proliferation following surgery (15, 16).”
BackgroundInfluentialDiabetes Mellitus and Increased Risk of Cancer: Focus on Metformin and the Insulin Analogs
McFarland, M. S., & Cripps, R. (2010) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.30.11.1159 · Cited by 50
“A retrospective review was conducted of the data of 2529 patients receiving neoadjuvant chemotherapy for early-stage breast cancer to determine if metformin use was associated with a significant change in pathologically confirmed complete response (pCR) rates.(37) Although definitions of pCR vary, broadly, it is consi…”
MethodFeng, Y. (2012) · Oncology Reports · doi:10.3892/or.2012.1745 · Cited by 50
“A recent study suggests that metformin could lower cancer risk, reduce the rate of cancer deaths (12,13), and kill cancer cells.”
ATM and LKB1 dependent activation of AMPK sensitizes cancer cells to etoposide-induced apoptosis
Luo, L., Huang, W., Tao, R., Hu, N., Xiao, Z. J., & Luo, Z. (2012) · Cancer Letters · doi:10.1016/j.canlet.2012.08.034 · Cited by 51
“AMPK activity has been shown to be suppressed in human breast cancer and combination of metformin with other anti-cancer drugs in the treatment of breast cancer improves pathological responses [14; 15].”
BackgroundAssociation of Metformin Use with Outcomes in Advanced Endometrial Cancer Treated with Chemotherapy
Ezewuiro, O., Grushko, T. A., Kocherginsky, M., Habis, M., Hurteau, J. A., Mills, K. A., HUNN, J., Olopade, O. I., Fleming, G. F., & Romero, I. L. (2016) · PLoS ONE · doi:10.1371/journal.pone.0147145 · Cited by 51
The Pathway from Diabetes and Obesity to Cancer, on the Route to Targeted Therapy
Gallagher, E. J., Fierz, Y., Ferguson, R. D., & LeRoith, D. (2010) · Endocrine Practice · doi:10.4158/ep10098.ra · Cited by 50
Mtenga, D. V., & Ripanda, A. (2022) · Heliyon · doi:10.1016/j.heliyon.2022.e09586 · Cited by 49
Contributions of AMPK and p53 dependent signaling to radiation response in the presence of metformin
Muaddi, H., Chowdhury, S., Vellanki, R. N., Zamiara, P., & Koritzinsky, M. (2013) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2013.06.014 · Cited by 51
“It has been spurred on by retrospective data demonstrating that metformin users have higher rates of pathologic complete response during neoadjuvant chemotherapy for breast cancer [4].”
BackgroundMetformin: Its emerging role in oncology
Micić, D., Cvijović, G., Trajković, V., Duntas, L. H., & Polovina, S. P. (2011) · HORMONES · doi:10.14310/horm.2002.1288 · Cited by 48
“diabetic patients with breast tumors taking metformin and undergoing neoadjuvant chemotherapy compared with diabetic patients with breast tumor not taking metformin.(74) Furthermore, Garcia and Tisman have provided an additional explanation for this enhanced pathologic complete response, namely, that chronic metformin…”
ResultQiu, H., Rhoads, G. G., Berlin, J. A., Marcella, S. W., & Demissie, K. (2012) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12036 · Cited by 49
“[5] observed that diabetic breast cancer patients treated with metformin experienced a threefold greater pathologic complete response (pCR) rates with neoadjuvant chemotherapy than those”
BackgroundHwang, I. C., Park, S. M., Shin, D., Ahn, H. Y., Rieken, M., & Shariat, S. F. (2015) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2015.16.2.595 · Cited by 49
“, 2009); however subsequent studies showed no effect on the long-term, recurrencefree survival rate of patients with T2D (Jiralerspong et al., 2009; Patel et al., 2010).”
BackgroundGeriatric Oncology: An Overview of Progresses and Challenges
Extermann, M. (2010) · Cancer Research and Treatment · doi:10.4143/crt.2010.42.2.61 · Cited by 48
“cancer risk, risk of relapse, response to treatment (6,7)).”
BackgroundMartin, S. D., & McGee, S. L. (2019) · Cancer & Metabolism · doi:10.1186/s40170-019-0207-x · Cited by 48
Mao, X., Wu, S., Huang, D., & Li, C. (2024) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2024.03.006 · Cited by 53
The effect of metformin on breast cancer outcomes in patients with type 2 diabetes
Oppong, B. A., Pharmer, L. A., Oskar, S., Eaton, A. A., Stempel, M. M., Patil, S. N., & King, T. A. (2014) · Cancer Medicine · doi:10.1002/cam4.259 · Cited by 47
“[41] found that diabetic patients with BC treated with metformin experienced higher pathologic response rates after neoadjuvant chemotherapy than those treated with other diabetic medications (24% vs.”
ResultTeixeira, S. F., Guimarães, I. D. S., Madeira, K. P., Daltoé, R. D., Silva, I. V., & Rangel, L. B. A. (2013) · Jornal Brasileiro de Pneumologia · doi:10.1590/s1806-37132013000600002 · Cited by 47
Ahmed, I., Ferro, A., Cohler, A., Langenfeld, J. E., Surakanti, S. G., Aisner, J., Zou, W., Haffty, B. G., & Jabbour, S. K. (2015) · PubMed Central · doi:10.3978/j.issn.2072-1439.2014.12.32 · Cited by 46
Zou, Y., Xie, C., Yang, S., & Xiong, J. (2016) · Molecular Medicine Reports · doi:10.3892/mmr.2016.6094 · Cited by 47
“Metformin in particular has been used in several clinical trials (13-15).”
Chong, C. R., & Chabner, B. A. (2009) · The Oncologist · doi:10.1634/theoncologist.2009-0286 · Cited by 47
Cai, H., Zhang, Y., Han, T. K., Everett, R. S., & Thakker, D. R. (2016) · International Journal of Cancer · doi:10.1002/ijc.29965 · Cited by 46
“chemotherapy for breast cancer versus diabetic patients not on metformin (8%) or nondiabetic patients (16%).(14) An asso-”
BackgroundUse of Metformin and Survival of Diabetic Women with Breast Cancer
Peeters, P. J. H. L., Bazelier, M. T., Vestergaard, P., Leufkens, H. G. M., Schmidt, M. K., de Vries, F., & Bruin, M. L. D. (2013) · Current Drug Safety · doi:10.2174/15680266113136660069 · Cited by 46
Wang, F., Liu, Z., Zeng, J.-S., Zhu, H., Li, J., Cheng, X., Jiang, T., Zhang, L., Zhang, C., Chen, T., et al. (2015) · Leukemia Research · doi:10.1016/j.leukres.2015.09.016 · Cited by 46
Insulin Breast Cancer Connection: Confirmatory Data Set the Stage for Better Care
DeCensi, A., & Gennari, A. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.3022 · Cited by 45
Koh, M., Lee, J., Min, C., & Moon, A. (2013) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2013.02.015 · Cited by 46
Therapeutic potential of metformin in papillary thyroid cancer in vitro and in vivo
Cho, S. W., Yi, K. H., Han, S. K., Sun, H. J., Kim, Y. A., Oh, B., Park, Y. J., & Park, D. J. (2014) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2014.05.021 · Cited by 46
Kiderlen, M., de Glas, N. A., Bastiaannet, E., Engels, C. C., van de Water, W., de Craen, A. J. M., Portielje, J. E. A., van de Velde, C. J. �., & Liefers, G. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt367 · Cited by 46
Role of p53 Family Proteins in Metformin Anti-Cancer Activities
Yi, Y., Zhang, W., Yi, J., & Xiao, Z. J. (2019) · Journal of Cancer · doi:10.7150/jca.30659 · Cited by 47
“Currently, more than 300 FDA-approved clinical trials are undergoing investigation of metformin anti-cancer activity, including numerous studies that use a combination of metformin with other drugs such as afatinib [59], sorafenib [79] and chemotherapeutic drugs[48, 140].”
BackgroundKim, N., Lee, H., & Lee, C. (2015) · International Journal of Oncology · doi:10.3892/ijo.2015.3004 · Cited by 45
Vissers, P. A. J., Cardwell, C. R., van de Poll-Franse, L. V., Young, I. S., Pouwer, F., & Murray, L. (2015) · Breast Cancer Research and Treatment · doi:10.1007/s10549-015-3331-5 · Cited by 45
“cancer patients[25].”
Low and high linear energy transfer radiation sensitization of HCC cells by metformin
Kim, E. H., Kim, M.-S., Cho, C.-K., Jung, W., Jeong, Y. K., & Jeong, J.-H. (2013) · Journal of Radiation Research · doi:10.1093/jrr/rrt131 · Cited by 45
“Treatment response rates are higher in patients treated with metformin in cohort studies of breast cancer treated with neoadjuvant chemotherapy [8], in head and neck cancer treated with radiation [9], and in esophageal cancer treated with chemoradiotherapy [10].”
BackgroundObesity and cancer treatment efficacy: Existing challenges and opportunities
Ross‐Driscoll, K., Gogineni, K., Subhedar, P. D., Lin, J. Y., & McCullough, L. E. (2019) · Cancer · doi:10.1002/cncr.31976 · Cited by 45
Lee, J., Sul, J. Y., Park, J. T., Lee, M., Cha, E., & Ko, Y. (2019) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2019.4122 · Cited by 45
“clinical data have also confirmed that metformin may improve the overall survival of patients with diabetes and cancer either alone or in combination with chemotherapy (11,12).”
BackgroundChromosomal instability causes sensitivity to metabolic stress
Shaukat, Z., Liu, D., Choo, A., Hussain, R., O’Keefe, L. V., Richards, R. I., Saint, R. B., & Gregory, S. L. (2014) · Oncogene · doi:10.1038/onc.2014.344 · Cited by 44
Use of ACE Inhibitors and Angiotensin Receptor Blockers and Primary Breast Cancer Outcomes
Chae, Y. K., Brown, E. N., Lei, X. J., Melhem‐Bertrandt, A., Giordano, S. H., Litton, J. K., Hortobágyi, G. N., Gonzalez-Angulo, A. M., & Chávez‐MacGregor, M. (2013) · Journal of Cancer · doi:10.7150/jca.6888 · Cited by 44
“We also controlled for metformin and beta-blocker use as we previously demonstrated an association between them and pCR and OS, respectively[24, 26], although other mediation data including aspirin has not been collected[37].”
BackgroundMethodResultInfluentialSelf-citationAbdelgadir, E., Ali, R., Rashid, F., & Bashier, A. M. (2017) · Journal of Clinical Medicine Research · doi:10.14740/jocmr2922e · Cited by 45
“Metformin reported a better pathologic complete response rate when taken regardless if the patient had diabetes or not [44].”
BackgroundTroncone, M. J., Cargnelli, S., Villani, L. A., Isfahanian, N., Broadfield, L. A., Zychla, L., Wright, J., Pond, G. R., Steinberg, G. R., & Tsakiridis, T. K. (2017) · Oncotarget · doi:10.18632/oncotarget.17496 · Cited by 45
“This was also observed by retrospective analysis in other tumors such as esophageal, head and neck and prostate cancer [135-140].”
Memmott, R. M., & Dennis, P. A. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.3963 · Cited by 44
Lin, Y., Liu, Y., Gao, Z., Jing, D., Bi, R., Cui, X., Cao, Q., Zhao, Q., Gao, R., Su, Y., et al. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.175718 · Cited by 43
Rieken, M., Kluth, L. A., Xylinas, E. N., Fajković, H., Becker, A., Karakiewicz, P. I., Herman, M. P., Lotan, Y., Seitz, C., Schramek, P., et al. (2013) · World Journal of Urology · doi:10.1007/s00345-013-1171-7 · Cited by 43
Anticancer Effects of Metformin and Its Potential Use as a Therapeutic Agent for Breast Cancer
Guppy, A., Jamal‐Hanjani, M., & Pickering, L. M. (2011) · Future Oncology · doi:10.2217/fon.11.49 · Cited by 42
Chen, L., Chubak, J., Boudreau, D. M., Barlow, W. E., Weiss, N. S., & Li, C. I. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0687 · Cited by 43
Pujalte‐Martin, M., Borchiellini, D., Thamphya, B., Guillot, A., Paoli, J.-B., Besson, D., Hilgers, W., Priou, F., Kouri, C. E., Hoch, B., et al. (2021) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2021.08.008 · Cited by 44
Oral Antihyperglycemic Treatment Options for Type 2 Diabetes Mellitus
Brietzke, S. (2014) · Medical Clinics of North America · doi:10.1016/j.mcna.2014.08.012 · Cited by 44
“In another study of patients with diagnosed breast cancer, complete response to neoadjuvant chemotherapy occurred in 24% of metformintreated patients with T2DM, versus 8% of non–metformin-treated patients with T2DM, and in 16% of nondiabetic individuals.(10) A hospital-based study of pancreatic adenocarcinoma identifi…”
ResultVélez, J., Pan, R. A., Lee, J. T. C., Enciso, L. J., Suarez, M., Duque, J. E., Jaramillo, D., López, C., Morales, L., Bornmann, W. G., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.9843 · Cited by 41
“Metformin is a very attractive combination partner as its safety has been demonstrated when used alone or combined with traditional chemotherapeutic schemes in several clinical trials [42–45].”
Metformin: an old drug with new potential
Hajjar, J., Habra, M. A., & Naing, A. (2013) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2013.833604 · Cited by 42
“Metformin was independently predictive of a pathologic complete response [55].”
BackgroundMatuschek, C., Bölke, E., Roth, S. L., Orth, K., Lang, I., Bojar, H., Janni, J. W., Audretsch, W., Nestle-Kraemling, C., Lammering, G., et al. (2012) · Strahlentherapie und Onkologie · doi:10.1007/s00066-012-0162-8 · Cited by 41
More favorable progesterone receptor phenotype of breast cancer in diabetics treated with metformin
Berstein, L. M., Boyarkina, M. P., Tsyrlina, E. V., Turkevich, E. A., & Семиглазов, В. Ф. (2010) · Medical Oncology · doi:10.1007/s12032-010-9572-6 · Cited by 41
“Besides, breast cancer patients with diabetes receiving metformin and neoadjuvant chemotherapy had a higher pathologic complete response (pCR) rate than did diabetics not receiving metformin [16].”
ResultMolecular Radiobiology: The State of the Art
Giaccia, A. J. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.2776 · Cited by 39
“In one retrospective study of patients with breast cancer, the pathologic complete response was significantly higher in the cohort who received metformin and neoadjuvant chemotherapy compared with the group who did not receive metformin.(27) In another retrospective study, a similar advantage in terms of higher pathol…”
ResultMetformin may protect nondiabetic breast cancer women from metastasis
El-Haggar, S. M., El‐Shitany, N. A., Mostafa, M. F., & El‐Bassiouny, N. A. (2016) · Clinical & Experimental Metastasis · doi:10.1007/s10585-016-9782-1 · Cited by 42
Mayer, M., Klotz, L. H., & Venkateswaran, V. (2016) · The Journal of Urology · doi:10.1016/j.juro.2016.10.069 · Cited by 41
Cao, X., Wen, Z., Wang, X., Li, Y., Liu, K., & Wang, X. (2017) · Journal of Cancer · doi:10.7150/jca.19750 · Cited by 40
“has reported increased pathologically complete responses of early-stage breast cancer patients undergoing neo-adjuvant therapy who had received metformin treatment compared with those who had received non-metformin treatment [47].”
BackgroundWelch, M. R., & Grommes, C. (2013) · CNS Oncology · doi:10.2217/cns.13.12 · Cited by 41
Yates, M. S., Coletta, A. M., Zhang, Q., Schmandt, R. E., Medepalli, M., Nebgen, D. R., Soletsky, B. R., Milbourne, A. M., Levy, E. J., Fellman, B. M., et al. (2018) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-17-0398 · Cited by 40
Yam, C., Esteva, F. J., Patel, M. M., Raghavendra, A. S., Ueno, N. T., Moulder, S. L., Hess, K. R., Shroff, G. S., Hodge, S., Koenig, K. H., et al. (2019) · Investigational New Drugs · doi:10.1007/s10637-018-0700-z · Cited by 39
Metformin Impairs Glutamine Metabolism and Autophagy in Tumour Cells
Saladini, S., Aventaggiato, M., Barreca, F., Morgante, E., Sansone, L., Russo, M. A., & Tafani, M. (2019) · Cells · doi:10.3390/cells8010049 · Cited by 40
“Metformin is often used in gynaecological oncology as adjuvant drug to increase the efficacy of cisplatin-based neoadjuvant (NACT) chemotherapy [24], in neck and cervix cancer [46] and earlier-stage operable breast cancer [47].”
BackgroundMetformin: Metabolic Rewiring Faces Tumor Heterogeneity
Cioce, M., Pulito, C., Strano, S., Blandino, G., & Fazio, V. M. (2020) · Cells · doi:10.3390/cells9112439 · Cited by 41
“In therapeutic settings, improvement of overall survival (OS) was observed in breast, pancreatic, liver, colorectal and prostate cancer, generally in window-of-opportunity trials [70,71].”
BackgroundLyne, S. B., & Yamini, B. (2021) · Cancers · doi:10.3390/cancers13081953 · Cited by 42
Barakat, H. E., Hussein, R. R. S., Elberry, A. A., Zaki, M. A., & Ramadan, M. E. (2022) · Scientific Reports · doi:10.1038/s41598-022-11138-3 · Cited by 41
Hiding in plain view: the potential for commonly used drugs to reduce breast cancer mortality
Holmes, M. D., & Chen, W. Y. (2012) · Breast Cancer Research · doi:10.1186/bcr3336 · Cited by 40
“17) after adjustment for age, diabetes, BMI, stage, grade, ER status, and treatment) [45].”
Serageldin, M. A., Kassem, A. B., Elkerm, Y., Helmy, M. W., El‐Mas, M. M., & El‐Bassiouny, N. A. (2023) · Drug Safety · doi:10.1007/s40264-023-01305-4 · Cited by 39
Identification of a selective small molecule inhibitor of breast cancer stem cells
Germain, A. R., Carmody, L., Morgan, B., Fernández, C., Forbeck, E. M., Lewis, T. A., Nag, P. P., Ting, A., VerPlank, L., Feng, Y., et al. (2012) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2012.01.035 · Cited by 39
Khawaja, M. R., Nick, A. M., Madhusudanannair, V., Fu, S., Hong, D. S., McQuinn, L., Ng, C. S., Piha-Paul, S. A., Jankú, F., Subbiah, V., et al. (2016) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-016-3009-7 · Cited by 40
“In a retrospective study of patients with early-stage breast cancer, the rate of pathologic complete response was higher in the diabetic patients taking metformin than in the diabetic patients not taking metformin or in the non-diabetic patients [12].”
Self-citationKawashima, M., Tokiwa, M., Nishimura, T., Kawata, Y., Sugimoto, M., Kataoka, T. R., Sakurai, T., Iwaisako, K., Suzuki, E., Hagiwara, M., et al. (2019) · British Journal of Cancer · doi:10.1038/s41416-019-0662-8 · Cited by 42
Co-delivery of bufalin and nintedanib via albumin sub-microspheres for synergistic cancer therapy
Xu, Y. D., Liu, Y., Liu, Q., Lu, S., Chen, X., Xu, W., & Shi, F. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.08.049 · Cited by 40
Zhang, T., Wang, X., He, D., Jin, X., & Guo, P. (2014) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000116 · Cited by 39
Papadimitriou, K., Papademetriou, K., Ardavanis, A. S., & Kountourakis, P. (2010) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2072-1439.2010.02.03.8 · Cited by 38
Lin, H., Kachingwe, B. H., Lin, H., Cheng, H. W., Uang, Y., & Wang, L. (2013) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1334 · Cited by 39
From Genotype to Functional Phenotype: Unraveling the Metabolomic Features of Colorectal Cancer
Bathe, O. F., & Farshidfar, F. (2014) · Genes · doi:10.3390/genes5030536 · Cited by 39
“In breast cancer patients, metformin is associated with higher response rates to cytotoxic chemotherapy [117].”
BackgroundA review for clinicians: Prostate cancer and the antineoplastic properties of metformin
Hankinson, S. J., Fam, M. M., & Patel, N. N. (2016) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2016.10.009 · Cited by 40
Damelin, L. H., Jivan, R., Veale, R. B., Rousseau, A. L., & Mavri‐Damelin, D. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-314 · Cited by 38
“Since then, metformin has been observed to reduce the proliferation of many types of carcinoma cell lines and diabetic patients taking metformin have been found to have better recovery rates from breast cancer [14-17].”
BackgroundMetformin and cancer: licence to heal?
Papanas, N., Maltezos, E., & Mikhailidis, D. P. (2010) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2010.499122 · Cited by 37
“Although the exact mechanism(s) mediating the protective action of metformin need further clarification, some authors have already suggested that this drug may prove useful as an adjunctive antitumor agent [28,32,38,39], including nondiabetic patients [39].”
BackgroundInfluentialMüssig, K., Staiger, H., Kantartzis, K., Fritsche, A., Kanz, L., & Häring, H. (2010) · Diabetic Medicine · doi:10.1111/j.1464-5491.2010.03132.x · Cited by 37
Metronomic anti-cancer therapy – an ongoing treatment option for advanced cancer patients
Mross, K. B., & Steinbild, S. (2012) · journal of cancer therapeutics and research · doi:10.7243/2049-7962-1-32 · Cited by 36
“Besides, there are some drugs, which were developed and approved not for anti-cancer treatment but for other indications which later showed anti-angiogenic potency among other effects: cyclooxygenase-2 inhibitors (COX-2) [60,100,102], peroxisome proliferator-activated receptor-γ agonists (PPARγ) [82], metformin, nelfi…”
BackgroundDiabetes treatments and cancer risk: the importance of considering aspects of drug exposure
Walker, J. J., Johnson, J. A., & Wild, S. H. (2013) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70028-7 · Cited by 37
El‐Ashmawy, N. E., Khedr, N. F., El‐Bahrawy, H. A., & Mansour, H. E. A. (2017) · Tumor Biology · doi:10.1177/1010428317692235 · Cited by 38
Metformin suppresses breast cancer growth via inhibition of cyclooxygenase‑2
Shi, B., Hu, X., He, H., & Fang, W. (2021) · Oncology Letters · doi:10.3892/ol.2021.12876 · Cited by 40
Associations between diabetes medication use and risk of second breast cancer events and mortality
Calip, G. S., Yu, O., Hoskins, K. F., & Boudreau, D. M. (2015) · Cancer Causes & Control · doi:10.1007/s10552-015-0599-z · Cited by 37
“As such, metformin is associated with increased rates of pathologic complete response after chemotherapy [17] and reduced tumor proliferation markers in BC patients without diabetes [18].”
Cracking Open Window of Opportunity Trials
Kalinsky, K. M., & Hershman, D. L. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.3293 · Cited by 37
Diabetes and Cancer: Metabolic Association, Therapeutic Challenges, and the Role of Natural Products
Talib, W. H., Mahmod, A. I., Abuarab, S. F., Hasen, E., Munaim, A. A., Haif, S. K., Ayyash, A. M., Khater, S. H., Al-Yasari, I. H., & Kury, L. T. A. (2021) · Molecules · doi:10.3390/molecules26082179 · Cited by 38
“A retrospective study was carried out by MD Anderson Cancer Centre in order to determine whether treatment with metformin had affected the pathologic complete response (pCR) rates in females with both diabetes and breast cancer on treatment with neoadjuvant chemotherapy [128].”
MethodShah, S., Mansour, H. M., Aguilar, T. M., & Lucke-Wold, B. P. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25115694 · Cited by 36
“Investigators have suggested a reduced cancer incidence and mortality in individuals treated with metformin, warranting its potential as an adjunctive therapy in cancer management [21].”
BackgroundTargeting AMPK in the treatment of malignancies
Vakana, E., Altman, J. K., & Platanias, L. C. (2011) · Journal of Cellular Biochemistry · doi:10.1002/jcb.23369 · Cited by 37
“In addition, among diabetic patients with breast cancer on neoadjuvant therapy, those receiving metformin were found to have higher chance to achieve complete remissions (CR) than those not receiving metformin [Jiralerspong et al., 2009].”
BackgroundHirsh, V., Ko, A., Pilot, R., Renschler, M. F., & Socinski, M. A. (2016) · Clinical Lung Cancer · doi:10.1016/j.cllc.2016.04.002 · Cited by 36
Kumar, A., Al-Sammarraie, N., DiPette, D. J., & Singh, U. S. (2014) · Oncotarget · doi:10.18632/oncotarget.2606 · Cited by 38
“In recent years, oncologists are paying considerable attention to metformin as some populationbased studies showed a low cancer incidence and mortality among diabetic patients treated with metformin [8-13].”
Farr, A., Stolz, M., Baumann, L., Bagó-Horváth, Z., Oppolzer, E., Pfeiler, G., Seifert, M., & Singer, C. F. (2017) · The Breast · doi:10.1016/j.breast.2017.04.001 · Cited by 36
Chand, M., Keller, D. S., Mirnezami, R., Bullock, M. D., Bhangu, A. A., Moran, B. J., Tekkis, P. P., Brown, G. M., Mirnezami, A., & Berho, M. E. (2018) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v10.i7.145 · Cited by 36
Insulin-Sensitizers, Polycystic Ovary Syndrome and Gynaecological Cancer Risk
Lauretta, R., Lanzolla, G., Vici, P., Mariani, L., Moretti, C., & Appetecchia, M. (2016) · International Journal of Endocrinology · doi:10.1155/2016/8671762 · Cited by 36
“in a retrospective study of 2529 diabetic patients, including 68 on metformin and 87 not, showed that diabetic patients affected with breast cancer and treated with metformin had higher rates of complete response to neoadjuvant chemotherapy than those not taking metformin [73].”
Background
Metadata
- Authors
- Jiralerspong, S., Palla, S. L., Giordano, S. H., Meric-Bernstam, F., Liedtke, C., Barnett, C. M., Hsu, L., Hung, M.-C., Hortobagyi, G. N., & Gonzalez-Angulo, A. M.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- From the Departments of Breast Medical Oncology, Biochemistry and Molecular Biology, Quantitative Sciences, Surgical Oncology, Pharmacy, Molecular and Cellular Oncology, and Systems Biology, The University of Texas M. D. Anderson Cancer Center, Houston, TX; and the Department of Gynecology and Obstetrics, University of Muenster, Muenster, Germany.
- Venue
- Journal of Clinical Oncology
- Published
- 2009-07-10
- Volume
- 27
- Issue
- 20
- Pages
- 3297-3302
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- PMC
- PMC2736070
- OpenAlex
- W2171998898
- Cited by
- 880
- References
- 42
- Citations by year
- 2026: 12 · 2025: 15 · 2024: 18 · 2023: 34 · 2022: 31 · 2021: 51 · 2020: 43 · 2019: 60 · 2018: 34 · 2017: 42 · 2016: 54 · 2015: 53 · 2014: 73 · 2013: 97 · 2012: 76
- FWCI
- 35.26
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Clinical Oncology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- American Association for Cancer Research
- Breast Cancer Research Foundation
- Amgen
- American Society of Clinical Oncology
- Deutsche Forschungsgemeinschaft
- National Institutes of Health (5k23ca121994-03)
- National Cancer Institute (1K23CA121994-01), K23-CA121994, 1K23CA121994)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Health Sciences › Medicine › Oncology › Cancer Risks and Factors
- Keywords
- metformin, breast cancer, diabetes mellitus, neoadjuvant chemotherapy, pathological complete response, predictors of treatment response
- MeSH terms
- Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Diabetes Mellitus, Female, Humans, Hypoglycemic Agents, Metformin, Middle Aged, Remission Induction, Multivariate Analysis, Logistic Models, Survival Analysis, Treatment Outcome, Neoadjuvant Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
